From the CEO's Desk
Swaroop Vakkalanka, PhD
Founder & CEO
Rhizen Pharma was founded with a vision to discover and develop novel onco-therapeutics designed to improve the quality of life of patients and drive transformative outcomes.
Rhizen is deeply committed to fulfilling this vision to address the immense unmet need that exists for patients living with cancer.
At Rhizen we practice
Fostering a culture of cutting-edge innovation as has been evidenced by our pivotal leadership in the “Targeted Drugs for Oncology & Inflammation” space through our focus on platforms that are fortified with foundational and expansive assets
Staying focused on the patient care with a relentless drive; tracking the evolution of relevant biology and explore remedies for challenges thrown
Creative collaboration and partnerships across global markets and research institutes
Purposeful communication to ensure the team’s focus on imaginative outcomes As we head into 2025 with aspirations to grow as full-fledged development company,
I firmly believe we are poised to make tangible difference to cancer care and to potentially bring to market innovative medicines. This is at the core of our philosophy and shapes the values at our company.
LA CHAUX DU FONDS, Switzerland--(BUSINESS WIRE)--Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S.
Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients
First study of RP7214, a DHODH inhibitor, in Covid-19 patients with mild, symptomatic disease on the background of promising preclinical efficacy & Phase 1 healthy volunteer safety
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients
Rhizen Pharma commences dosing in a phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/γ inhibitor with additional SIK3 activity) in patients with locally advanced or metastatic breast cancer.
Dual inhibition of the delta and gamma isoforms of PI3K by RP6557 attenuated PDGF induced lung fibroblast proliferation and TGFβ-mediated IL-6 release. Effective translation of activity in an animal model of pulmonary fibrosis with potent antiinflammatory and anti-fibrotic activity especially in combination with pirfenidone
1365: Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/ Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open-Label Multi-Center Study (ASH 2021)
The combination of tenalisib and romidepsin demonstrated a favorable safety profile and promising anti-tumor activity in patients with R/R TCL
RP 12146 demonstrated growth inhibitory activity in BRCA mutant and non-BRCA mutant cancer cell lines, and anti-tumor activities in both tumor size and tumor weight in OVCAR-3 xenograft model.
The Rhizen Blog